Lutetium Lu-177

ITM Isotope Technologies Munich secured up to $262.5 million in debt financing from Blue Owl Capital to support commercial readiness and potential U.S. launch of ITM-11.

Y-mAbs Therapeutics presented preclinical pharmacokinetics data for CD38-SADA at the 2025 AACR Annual Meeting, demonstrating key insights into the protein's behavior in animal models.

ITM Isotope Technologies Munich and Alpha-9 Oncology have signed a supply agreement for Actinium-225, a rare medical radioisotope crucial for developing targeted cancer radiopharmaceuticals.

Novartis plans to invest $23 billion over five years to establish seven new facilities and expand three existing ones across the United States, enabling 100% end-to-end US production of key medicines.

Radiopharmaceuticals are emerging as a powerful precision medicine approach in oncology, with Novartis leading the market through FDA-approved therapies Lutathera and Pluvicto generating over $2.1 billion in 2024.